Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer (clinicaltrials.gov) - Oct 16, 2026 - P1 | N=32 | Active, not recruiting | Sponsor: University of Michigan Rogel Cancer Center | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2030 ➔ Feb 2030 | Trial primary completion date: Oct 2026 ➔ Feb 2027
Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
|